Sign In
Buy BLCO
Bausch + Lomb Earnings Calls
| Release date | Apr 29, 2026 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0800 |
| EPS Surprise | 33.33% |
| Revenue estimate | 1.216B |
| Revenue actual | 1.244B |
| Revenue Surprise | 2.33% |
| Release date | Feb 18, 2026 |
| EPS estimate | $0.350 |
| EPS actual | $0.320 |
| EPS Surprise | -8.57% |
| Revenue estimate | 1.385B |
| Revenue actual | 1.405B |
| Revenue Surprise | 1.42% |
| Release date | Oct 29, 2025 |
| EPS estimate | $0.160 |
| EPS actual | $0.180 |
| EPS Surprise | 12.50% |
| Revenue estimate | 1.383B |
| Revenue actual | 1.281B |
| Revenue Surprise | -7.40% |
| Release date | Jul 30, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0700 |
| EPS Surprise | 16.67% |
| Revenue estimate | 1.274B |
| Revenue actual | 1.278B |
| Revenue Surprise | 0.305% |
Last 4 Quarters for Bausch + Lomb
Below you can see how BLCO performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $13.71 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0700 |
| EPS surprise | 16.67% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $13.97 |
| Jul 25, 2025 | $14.32 |
| Jul 28, 2025 | $14.44 |
| Jul 29, 2025 | $14.65 |
| Jul 30, 2025 | $13.71 |
| Jul 31, 2025 | $13.63 |
| Aug 01, 2025 | $13.50 |
| Aug 04, 2025 | $13.72 |
| Aug 05, 2025 | $14.44 |
| 4 days before | -1.86% |
| 4 days after | 5.32% |
| On release day | -0.584% |
| Change in period | 3.36% |
| Release date | Oct 29, 2025 |
| Price on release | $15.47 |
| EPS estimate | $0.160 |
| EPS actual | $0.180 |
| EPS surprise | 12.50% |
| Date | Price |
|---|---|
| Oct 23, 2025 | $15.78 |
| Oct 24, 2025 | $15.52 |
| Oct 27, 2025 | $15.37 |
| Oct 28, 2025 | $15.20 |
| Oct 29, 2025 | $15.47 |
| Oct 30, 2025 | $15.14 |
| Oct 31, 2025 | $14.94 |
| Nov 03, 2025 | $15.25 |
| Nov 04, 2025 | $15.00 |
| 4 days before | -1.96% |
| 4 days after | -3.04% |
| On release day | -2.13% |
| Change in period | -4.94% |
| Release date | Feb 18, 2026 |
| Price on release | $17.67 |
| EPS estimate | $0.350 |
| EPS actual | $0.320 |
| EPS surprise | -8.57% |
| Date | Price |
|---|---|
| Feb 11, 2026 | $17.03 |
| Feb 12, 2026 | $16.73 |
| Feb 13, 2026 | $17.03 |
| Feb 17, 2026 | $17.73 |
| Feb 18, 2026 | $17.67 |
| Feb 19, 2026 | $17.65 |
| Feb 20, 2026 | $17.94 |
| Feb 23, 2026 | $17.99 |
| Feb 24, 2026 | $18.44 |
| 4 days before | 3.76% |
| 4 days after | 4.36% |
| On release day | -0.113% |
| Change in period | 8.28% |
| Release date | Apr 29, 2026 |
| Price on release | $15.34 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0800 |
| EPS surprise | 33.33% |
| Date | Price |
|---|---|
| Apr 23, 2026 | $15.78 |
| Apr 24, 2026 | $15.82 |
| Apr 27, 2026 | $15.88 |
| Apr 28, 2026 | $15.72 |
| Apr 29, 2026 | $15.34 |
| Apr 30, 2026 | $15.90 |
| May 01, 2026 | $16.31 |
| May 04, 2026 | $16.30 |
| May 05, 2026 | $16.00 |
| 4 days before | -2.79% |
| 4 days after | 4.30% |
| On release day | 3.65% |
| Change in period | 1.39% |
Bausch + Lomb Earnings Call Transcript Summary of Q1 2026
Bausch + Lomb reported a strong start to 2026 with total Q1 revenue of $1.244 billion (6% constant currency growth) and significant margin expansion: adjusted EBITDA jumped 59% year-over-year to $200 million, with adjusted EBITDA margin up 500 basis points to 16.1%. Performance highlights: Pharmaceuticals grew 12% (driven by Miebo +33% and Xiidra +30%); Vision Care grew 5% led by Daily SiHy (up 23%) and LUMIFY (+15%); Surgical grew 1% but showed traction in premium IOLs (+27%) despite near-term headwinds (weather disruption, U.S. field force rebuild). The company increased R&D investment (R&D +15% / $101M in Q1) while improving adjusted SG&A (down ~340 bps) and adjusted gross margin (61.2%, +170 bps). Management emphasized durable, diversified growth, operating-leverage improvements (Vision '27 initiatives), and active pipeline progress (NDA filed for LUMIFY NXT, CE submission for seeLYRA, PreserVision AREDS3 launch). Guidance was raised: full-year revenue to $5.42–5.52B (up $45M) and adjusted EBITDA to $1.01–1.06B (up $10M), implying ~19% EBITDA margin at the midpoint. Management reiterated focus on converting revenue growth into high-quality earnings, progressing deleveraging toward a 3.5x net leverage target by 2028, and expecting sequential improvement in Surgical and Contact Lens businesses through the year.
